TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25256545

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) above the upper limit of autoregulation (ULA) during CPB
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for >48 h
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Preoperative antidepressant use
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Prior stroke
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Age (per year of age)
Number of subjects: 491
Study: 25256566

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) metabolomic profiling of spent culture media from embryos
Number of subjects: 161
Study: 25257635

Group type: EXPERIMENTAL
Intervention: Lotus valve system
Number of subjects: 120
Study: 25258026

Group type: EXPERIMENTAL
Intervention: Post-operative growth assessment
Number of subjects: 0
Study: 25258037

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study: 25260365

Group type: EXPERIMENTAL
Intervention: Estradiol (6 mg/day for 3 months)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exemestane (after 3 months of estradiol)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-dose estradiol treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall effectiveness of treatment
Number of subjects: 13
Study: 25260842

Group type: EXPERIMENTAL
Intervention: tasisulam combined with 1,000 mg/m² gemcitabine HCl (days 1 and 15)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tasisulam combined with 60 mg/m² docetaxel
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tasisulam combined with 200 mg/m²/day temozolomide
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tasisulam combined with 75 mg/m² cisplatin
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: tasisulam combined with 150 mg/day erlotinib
Number of subjects: 234
Study: 25261096

Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 109
Study: 25261424

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily with rifampicin thrice weekly
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily with rifampicin thrice weekly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Raltegravir alone (no rifampicin)
Number of subjects: 16
Study: 25261716

Group type: EXPERIMENTAL
Intervention: Homemade bilayer adhesive patch (AOS)
Number of subjects: 84
Study: 25261839

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin (400 mg) treatment for up to 48 weeks before liver transplantation
Number of subjects: 61
Study: 25262042

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PST plus antidepressant medications
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Antidepressant medications alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Overall depression treatment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Symptom Checklist-20
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Quality of life measures (SF-12, Minnesota Living with Heart Failure questionnaire, Sheehan Disability Scale)
Number of subjects: 97
Study: 25262126

Group type: EXPERIMENTAL
Intervention: Side branch predilatation
Number of subjects: 837
Study: 25262404

Group type: EXPERIMENTAL
Intervention: Pericoronitis pain symptoms
Number of subjects: 113
Study: 25264305

Group type: EXPERIMENTAL
Intervention: Crizotinib at the standard oral dose of 250 mg twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 50
Study: 25264814

Group type: EXPERIMENTAL
Intervention: GFAP-BDP levels measured within 24 hours using sandwich enzyme-linked immunosorbent assay
Number of subjects: 215

Group type: COMPARATOR
Intervention: Clinical screening alone
Number of subjects: 215
Study: 25264868

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients (MS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 34
Study: 25264981

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (10 mg/Kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise-training on treadmill
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin and simultaneous exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 25265186

Group type: EXPERIMENTAL
Intervention: Pandemrix vaccine (2009-10)
Number of subjects: 3518

Group type: EXPERIMENTAL
Intervention: Pandemrix vaccine (2010-11)
Number of subjects: 3518

Group type: EXPERIMENTAL
Intervention: Pandemrix or trivalent influenza vaccine (2010-11)
Number of subjects: 3518
Study: 25265315

Group type: COMPARATOR
Intervention: Ginseng
Number of subjects: 770
Study: 25267381

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 6 months
Number of subjects: 24
Study: 25267562

Group type: EXPERIMENTAL
Intervention: Surgical treatment (silicone metacarpophalangeal arthroplasty - SMPA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 169
Study: 25267741

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.88 mg/kg every 3 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.5 mg/kg dosing during 2 of 3 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (1.0 mg/kg weekly)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin
Number of subjects: 117
Study: 25267759

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy) at 50 mg/kg/day on post-transplantation days +3 and +4
Number of subjects: 92
Study: 25267796

Group type: EXPERIMENTAL
Intervention: Symptomatic severe hypoglycemia (HA)
Number of subjects: 503

Group type: COMPARATOR
Intervention: No hypoglycemia (Control)
Number of subjects: 503
Study: 25267955

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) levels > 30 µg/g
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined test using FC > 30µg/g and SIBDQ score < 6
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SIBDQ score
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein (CRP)
Number of subjects: 48
Study: 25268234

Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation (MV)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 1
Study: 25268768

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study: 25268986

Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Number of subjects: 34
Study: 25269577

Group type: EXPERIMENTAL
Intervention: Limited-compression ultrasound (LC US)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Incorporating LC US into the diagnostic approach
Number of subjects: 227
Study: 25270430

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (5 g/day: 1.9-2.2 g EPA; 1.1 g DHA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 210
Study: 25270899

Group type: EXPERIMENTAL
Intervention: Screened group (eye screening at 1-2 and 3-4 months)
Number of subjects: 11541

Group type: COMPARATOR
Intervention: Unscreened group (no eye screening at 6-9 months unless conspicuous or positive family history)
Number of subjects: 11541
Study: 25270908

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (n = 121)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT, n = 17)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (n = 93)
Number of subjects: 323
Study: 25271445

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions (0.5 mg/kg over 40 minutes)
Number of subjects: 97
Study: 25271871

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) treatment
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) reintroduction
Number of subjects: 257
Study: 25271941

Group type: EXPERIMENTAL
Intervention: Soy bars containing isoflavones, duration: 1 week
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Soy bars containing isoflavones
Number of subjects: 17
Study: 25272081

Group type: EXPERIMENTAL
Intervention: Oka-RIT (Varilrix™) vaccine, 2 doses at 4.5 and 6.5 months post transplantation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oka-RIT (Varilrix™) vaccine
Number of subjects: 45
Study: 25273116

Group type: EXPERIMENTAL
Intervention: Prucalopride 2-mg once-daily for 12 weeks
Number of subjects: 1596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1596
Study: 25273351

Group type: EXPERIMENTAL
Intervention: Primary prevention implantable cardioverter defibrillators (ICDs)
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Higher interleukin-6 levels
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: A score combining 5 biomarkers (C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T)
Number of subjects: 1189
Study: 25273854

Group type: EXPERIMENTAL
Intervention: Multifaceted tailored implementation strategy for delirium management
Number of subjects: 924
Study: 25274049

Group type: EXPERIMENTAL
Intervention: 6 week structured responsive exercise training programme (SRETP) on a training bike (three sessions per week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 39

Group type: COMPARATOR
Intervention: NACRT (neoadjuvant chemoradiotherapy)
Number of subjects: 39
Study: 25274394

Group type: EXPERIMENTAL
Intervention: Augmentation Pressure (AP)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Heart Rate-Adjusted Augmentation Index (AI75)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Previous Cardiovascular Disease (CVD)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Autonomic Dysfunction
Number of subjects: 676

Group type: COMPARATOR
Intervention: Retinopathy
Number of subjects: 676
Study: 25276415

Group type: EXPERIMENTAL
Intervention: Clonidine (4 µg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study: 25276665

Group type: EXPERIMENTAL
Intervention: Darunavir (Prezista(®)) with low-dose ritonavir (DRV/r) 600/100 mg twice daily
Number of subjects: 78
Study: 25277389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 0
Study: 25278335

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program (16 weeks, 3 times per week at 50% to >70% oxygen uptake reserve)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program
Number of subjects: 18
Study: 25279138

Group type: EXPERIMENTAL
Intervention: Computerized neuropsychological test battery
Number of subjects: 26
Study: 25279222

Group type: EXPERIMENTAL
Intervention: Romidepsin at 14 mg/m² as a 4-hour intravenous infusion on days 1, 8, and 15 of 28-day cycles for up to 6 cycles
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Romidepsin treatment
Number of subjects: 100
Study: 25279930

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comfort Score (CS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BIS 70.5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BIS ≤60
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sedation/analgesia using remifentanil and propofol
Number of subjects: 30
Study: 25280062

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) enoxaparin at a standard dose of 1 mg/kg every 12 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with malignancy and VTE
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cancer-free, age-matched, normal controls
Number of subjects: 10
Study: 25280575

Group type: EXPERIMENTAL
Intervention: Age over 75 years
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Interval between symptom onset and diagnosis below 7 months
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Decline of body weight before diagnosis exceeding 2 BMI units
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Functional Rating Score below 31 points
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall one-year mortality rate
Number of subjects: 176
Study: 25280913

Group type: EXPERIMENTAL
Intervention: Graph theoretical analysis of network parameters
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Graph theoretical analysis
Number of subjects: 120
Study: 25280960

Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 464
Study: 25281031

Group type: EXPERIMENTAL
Intervention: Copper histidine treatment (early treatment prior to onset of symptoms)
Number of subjects: 60
Study: 25281041

Group type: EXPERIMENTAL
Intervention: Old formulation of UFH
Number of subjects: 20

Group type: COMPARATOR
Intervention: New formulation of UFH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations of UFH
Number of subjects: 20
Study: 25281177

Group type: EXPERIMENTAL
Intervention: Trauma ultrasound performed by HEMS providers
Number of subjects: 293
Study: 25281400

Group type: EXPERIMENTAL
Intervention: Rifabutin dosed at 5 mg/kg three times a week
Number of subjects: 6
Study: 25281436

Group type: EXPERIMENTAL
Intervention: Multi-detector computed tomography angiography (MDCTA)
Number of subjects: 371
Study: 25282032

Group type: EXPERIMENTAL
Intervention: Higher urinary albumin-to-creatinine ratio (UACR)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Higher UACR
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Increased UACR
Number of subjects: 144
Study: 25283266

Group type: EXPERIMENTAL
Intervention: Axitinib at a starting dose of 5 mg b.i.d.
Number of subjects: 64
Study: 25283752

Group type: EXPERIMENTAL
Intervention: Rett syndrome females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milder mutations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milder clinical presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Puberty synchrony
Number of subjects: 0
Study: 25284275

Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment (80 mg initial dose, followed by 40 mg every-other-week for 16 weeks)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment
Number of subjects: 133
Study: 25284600

Group type: EXPERIMENTAL
Intervention: Extended criteria lungs transplanted after prolonged ex vivo lung perfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portable device for ex vivo lung perfusion
Number of subjects: 0
Study: 25284629

Group type: EXPERIMENTAL
Intervention: EndoAnchors used prophylactically for hostile proximal neck anatomy
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: EndoAnchors used for type Ia endoleak during initial endograft deployment
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: EndoAnchors used for endograft migration
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: EndoAnchors used in conjunction with extender cuffs after unsatisfactory endograft deployment
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Follow-up imaging after EndoAnchor implantation
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Primary prophylactic patients
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Revision patients treated for type Ia endoleak
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Sac regression >5 mm in patients with 1-year imaging
Number of subjects: 319
Study: 25285006

Group type: EXPERIMENTAL
Intervention: Kynurenine/tryptophan ratio
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum IL-1β concentrations
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum ratios of IL-18/IL-10
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum ratios of IFNγ/IL-10
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum ratios of IL-1β/IL-10
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum IL-1β
Number of subjects: 86
Study: 25285126

Group type: EXPERIMENTAL
Intervention: MenACYW-D (two doses at 12 and 18 months)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Meningococcal serogroup C conjugate vaccine (MCC, one dose at 12 months)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib (administered concomitantly with MenACYW-D)
Number of subjects: 123
Study: 25285269

Group type: EXPERIMENTAL
Intervention: Initial spirometry for COPD diagnosis
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Confirmatory spirometry after three months
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Treatment with tiotropium for newly diagnosed COPD patients
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Initial and confirmatory spirometry
Number of subjects: 187
Study: 25285572

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No protease inhibitors (Control)
Number of subjects: 33
Study: 25286053

Group type: EXPERIMENTAL
Intervention: Rapamycin treatment before the first islet infusion; induction therapy with anti-thymocyte globulin (ATG); short-term treatment with steroids and interleukin-1Ra; maintenance therapy with rapamycin+mycophenolate mofetil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Induction therapy with anti-thymocyte globulin (ATG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maintenance immunosuppression
Number of subjects: 10
Study: 25286173

Group type: EXPERIMENTAL
Intervention: β-lactam and macrolide combination treatment
Number of subjects: 580

Group type: COMPARATOR
Intervention: β-lactam monotherapy
Number of subjects: 580
Study: 25287104

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 120
Study: 25287572

Group type: EXPERIMENTAL
Intervention: Trisomy X girls (35 subjects)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls (70 subjects)
Number of subjects: 35
Study: 25287822

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg per day plus capecitabine 1,500 mg/m2 per day
Number of subjects: 72
Study: 25288018

Group type: EXPERIMENTAL
Intervention: Weekly rituximab consolidation (375 mg/m², four times infusion) after four cycles of R-CHOP21
Number of subjects: 51

Group type: COMPARATOR
Intervention: Historical case-matched control group treated with six cycles of R-CHOP21
Number of subjects: 51
Study: 25288099

Group type: EXPERIMENTAL
Intervention: Incontinence Utility Index (IUI)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Multi-attribute utility function (MAUF)
Number of subjects: 442
Study: 25288198

Group type: EXPERIMENTAL
Intervention: CV9202 vaccination combined with local radiation (5 GY per day for four successive days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CV9202 vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local radiation
Number of subjects: 0
Study: 25288566

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med-Diet) adherence
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: History of stroke/TIA
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Olive oil consumption
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 801
Study: 25289522

Group type: EXPERIMENTAL
Intervention: Oseltamivir, single 75 mg dose administered before APD treatment.
Number of subjects: 10
Study: 25290090

Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg once daily plus capecitabine 1000 mg m(-2) twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bosutinib plus capecitabine
Number of subjects: 32
Study: 25290534

Group type: EXPERIMENTAL
Intervention: Lumen-apposing covered self-expanding metal stent (LACSEMS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Double-pigtail stents (control)
Number of subjects: 33
Study: 25292153

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25293603

Group type: EXPERIMENTAL
Intervention: Observation as a management strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hernia repair
Number of subjects: 0
Study: 25293768

Group type: EXPERIMENTAL
Intervention: Rituximab (4 infusions of 375 mg/m²)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Rituximab (2 fixed 1-g infusions 2 weeks apart)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 248
Study: 25293773

Group type: EXPERIMENTAL
Intervention: Local radiotherapy to solitary lymphoma nodes and intranodal injections of low-dose rituximab (5 mg), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor, repeated 3 times targeting different lymphoma nodes
Number of subjects: 14
Study: 25294897

Group type: EXPERIMENTAL
Intervention: Refametinib plus sorafenib (refametinib 50 mg twice daily, sorafenib 200 mg morning/400 mg evening, with possible escalation to 400 mg twice daily from cycle 2)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Refametinib plus sorafenib
Number of subjects: 95
Study: 25295410

Group type: EXPERIMENTAL
Intervention: Smokers with a history of pneumothorax
Number of subjects: 9062

Group type: EXPERIMENTAL
Intervention: Increased percent CT emphysema
Number of subjects: 9062

Group type: EXPERIMENTAL
Intervention: Increased pleural-based emphysema
Number of subjects: 9062

Group type: EXPERIMENTAL
Intervention: Lifetime smoking intensity
Number of subjects: 9062
Study: 25295432

Group type: EXPERIMENTAL
Intervention: Antipsychotic-treated patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 25295500

Group type: EXPERIMENTAL
Intervention: self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc)
Number of subjects: 9